globalantitrust.com
U.S. update: FTC’s aggressive scrutiny of generic pharma deals
4-to-3 deals raise level of FTC scrutiny in generic pharma sector In what should be of interest to pharmaceutical companies’ deal teams and in-house counsel looking for strategic expansion op…